<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01312168</url>
  </required_header>
  <id_info>
    <org_study_id>201012085RB</org_study_id>
    <nct_id>NCT01312168</nct_id>
  </id_info>
  <brief_title>Endothelial Dysfunction, Monocyte Activation, and Vasculopathy in Patients With Obstructive Sleep Apnea (OSA) and Effect of 6-month CPAP Treatment</brief_title>
  <official_title>Endothelial Dysfunction, Monocyte Activation, and Vasculopathy in Patients With Obstructive Sleep Apnea and Effect of Six-month CPAP Treatment: A Large-scale, Double-blind, Randomized, Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>China Medical University, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This purpose of this study is to&#xD;
&#xD;
        1. Determine the change in endothelial dependent vascular reactivity and vascular&#xD;
           properties&#xD;
&#xD;
        2. Determine the changes in monocytes activation&#xD;
&#xD;
        3. Determine the change in pro-inflammatory status&#xD;
&#xD;
        4. Investigate the effect of six-month CPAP therapy on the above changes in patients with&#xD;
           OSA&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obstructive sleep apnea (OSA), characterized with chronic intermittent hypoxia (CIH) and&#xD;
      sleep fragmentation, is associated with three-fold higher risk of cardiovascular events. CIH&#xD;
      could promote production of ROS which induced the adhesion of circulating monocytes,&#xD;
      endothelium injury, and production of pro-inflammatory mediators and adhesion molecules and&#xD;
      lead to formation of atherosclerotic plaque. Recent studies showed vascular endothelium&#xD;
      function could be noninvasively assessed with Flow-mediated dilation (FMD) in brachial&#xD;
      artery, whereas OSA patients have lower FMD compared to control subjects. However, the CPAP&#xD;
      effects on vascular function have conflicting results. Conflicts usually involve the small&#xD;
      sample size, lack of appropriate control, and inadequate control of confounding factors, like&#xD;
      physical activity, and duration of CPAP treatment. Also, CPAP effect on other monocytes&#xD;
      activation and inflammatory mediators are clear as well. Our previous studies showed 12-week&#xD;
      CPAP treatment could not modify the levels of TNF-Î± and hsCRP. However, the 12-week treatment&#xD;
      may be not long enough to draw the conclusions for benefit from long-term CPAP therapy.&#xD;
      Therefore, we plan to conduct a cross-sectional followed by a double blind, randomized,&#xD;
      placebo-control, parallel-group interventional study to prove our hypothesis that OSA can&#xD;
      lead to endothelial dysfunction, monocytes activation, and pro-inflammatory state which leads&#xD;
      to and vasculopathy and those changes can be reverted by CPAP.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>vascular reactivity of brachial artery and pulse wave velocity</measure>
    <time_frame>six months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>percentage of adhesion molecule expression on monocytes</measure>
    <time_frame>six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>levels of extra and intracellular cytokine</measure>
    <time_frame>six months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Sleep Apnea, Obstructive</condition>
  <condition>Continuous Positive Airway Pressure</condition>
  <condition>Endothelium</condition>
  <condition>Inflammation</condition>
  <condition>Vascular Function</condition>
  <arm_group>
    <arm_group_label>Healthy non-OSA control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>OSA receiving therapeutic CPAP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>OSA receiving subtherapeutic CPAP</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Therapeutic CPAP</intervention_name>
    <description>CPAP ventilator, optimal pressure decided by CPAP manual titration, daily use at sleep, six months</description>
    <arm_group_label>OSA receiving therapeutic CPAP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Subtherapeutic CPAP</intervention_name>
    <description>Subtherapeutic CPAP ventilator, pressure &lt;3 cmH2O, daily use at sleep, six months</description>
    <arm_group_label>OSA receiving subtherapeutic CPAP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        OSA patients&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  male patients aged 30 to 65 year who have daytime sleepiness (ESS&gt;=10)&#xD;
&#xD;
          -  newly diagnosed OSA (AHI&gt;30/hr) by overnight PSG but never been treated&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  unwilling or unable to perform testing procedure&#xD;
&#xD;
          -  past or current smoking history&#xD;
&#xD;
          -  medical condition (including cardiovascular disease, chronic pulmonary disease,&#xD;
             diabetes, endocrinologic disease, chronic renal failure, and psychiatric disease)&#xD;
&#xD;
          -  systemic inflammatory conditions (system lupus erythematosus, rheumatoid arthritis,&#xD;
             sarcoidosis, Crohn's disease, and ulcerative colitis)&#xD;
&#xD;
          -  active neurologic event&#xD;
&#xD;
          -  active infection two weeks prior to screening&#xD;
&#xD;
          -  enrolled in other trials in the study period&#xD;
&#xD;
          -  other sleep disorders&#xD;
&#xD;
          -  sleepy driver&#xD;
&#xD;
          -  using maintenance medications&#xD;
&#xD;
        Control subjects&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Age-, sex-, body weight-, height-matched subjects with enrolled OSA patients&#xD;
&#xD;
          -  non-sleepy&#xD;
&#xD;
          -  no OSA confirmed by home sleep study (AHI&lt;5/hr)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  unwilling or unable to perform testing procedure&#xD;
&#xD;
          -  past or current smoking history&#xD;
&#xD;
          -  medical condition (including cardiovascular disease, chronic pulmonary disease,&#xD;
             diabetes, endocrinologic disease, chronic renal failure, and psychiatric disease)&#xD;
&#xD;
          -  systemic inflammatory conditions (system lupus erythematosus, rheumatoid arthritis,&#xD;
             sarcoidosis, Crohn's disease, and ulcerative colitis)&#xD;
&#xD;
          -  active neurologic event&#xD;
&#xD;
          -  active infection two weeks prior to screening&#xD;
&#xD;
          -  enrolled in other trials in the study period&#xD;
&#xD;
          -  other sleep disorders&#xD;
&#xD;
          -  using maintenance medications&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peilin Lee, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>March 8, 2011</study_first_submitted>
  <study_first_submitted_qc>March 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2011</study_first_posted>
  <last_update_submitted>December 12, 2016</last_update_submitted>
  <last_update_submitted_qc>December 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiovascular disease</keyword>
  <keyword>Continuous positive airway pressure</keyword>
  <keyword>Endothelium</keyword>
  <keyword>Vascular function</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Sleep Apnea</keyword>
  <keyword>Obstructive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

